SMTL ID : 2xp2.1

Structure of the Human Anaplastic Lymphoma Kinase in Complex with Crizotinib (PF-02341066)

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.90 Å

Oligo State

monomer

Ligands

1 x VGH: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine(Non-covalent)

VGH.1: 15 residues within 4Å: Chain A: L.38, V.46, A.64, L.112, E.113, L.114, M.115, A.116, G.117, G.118, R.169, N.170, L.172, G.185, D.186 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:L.38, A:L.112, A:L.172 Hydrogen bonds: A:E.113, A:M.115 Halogen bonds: A:G.185

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Cui, J.J. et al., Structure Based Drug Design of Crizotinib (Pf-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (C-met) Kinase and Anaplastic Lymphoma Kinase (Alk). J.Med.Chem (2011)

Release Date

2010-09-15

Peptides

TYROSINE-PROTEIN KINASE RECEPTOR: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

TYROSINE-PROTEIN KINASE RECEPTOR

Related Entries With Identical Sequence